Resident Publications – March 2015

Drs. George Ou and Neal Shahidi – World Journal of Gastroenterology

Drs. Shahidi and Ou, along with colleagues from the gastroenterology department at UBC were published in the World Journal of Gastroenterology. Their study Effect of longer battery life on small bowel capsule endoscopy aimed to determine if longer battery life improves capsule endoscopy (CE) completion rates. They found that for patients with altered bowel anatomy had higher completion rates with longer battery life capsules. They recommend a randomized control trial to confirm their findings.

Dr. Martin Hyrcza – American Journal of Surgical Pathology

Dr. Martin Hyrcza was an author on a paper published in the March 2015 edition of the American Journal of Surgical Pathology. This study examines the presence of the EWSR1 rearrangement in a variety of clear cell salivary gland carcinomas with myoepithelial differentiation.

Read the full article

Dr. Nawaaz Nathoo – Journal of Neuro-Ophthalmology

Dr. Nawaaz Nathoo, and his co-authors were published in the March edition of the Journal of Neuro-Ophthalmology for their research on the association between phoshodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy. They did not find an association between having a prescription filled for PDE-5 inhibitor medication and receiving a diagnosis code for NAION.

Dr. Martin Smoragiewicz – The Lancet Oncology

Dr. Smoragiewicz was a part author on an article published in The Lancet Oncology, “The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study” which found that the international metastic renal cell carcinoma database consortium (IMDC) prognostic model can be applied to patients previously treated with targeted therapy, in addition to previously validated populations in first-line targeted therapy. The IMDC prognostic model in the second-line targeted therapy setting has an improved prognostic performance and is applicable to a more contemporary patient cohort than that of the three-factor MSKCC model.

Tags for this post

author: Michelle Seymour